EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial

Nichola Cooper iD, Waleed Ghanima, Nicola Vianelli, David Valcárcel, İrfan Yavaşoğlu iD, Anait Melikyan, Eduardo Yañez Ruiz, Jens Haenig, Olivier Somenzi, James Lee, Joan Clark, Yifan Zhang und 1 weitere

American Journal of Hematology · 2024-01 · 99 (1) · 57-67

DOI: 10.1002/ajh.27131 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 28.11.2023. Verfasst von Nichola Cooper und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, UK. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is characterized by reduced platelet count due to increased destruction and is categorized according to the time following diagnosis (newly diagnosed, persistent, chronic). First‐line corticosteroid therapy is associated with transient response, high relapse rates, and considerable toxicity. TAPER (NCT03524612) is a Phase II, prospective, single‐arm trial investigating whether eltrombopag can induce a sustained response off‐treatment (SRoT) in adult patients with ITP after first‐line corticosteroid failure. This study defines SRoT as an off‐treatment period wherein platelet count remains above 30 × 10 9 /L in the absence of bleeding or rescue therapy. The primary endpoint was the proportion of patients who achieved SRoT until Month 12, which was 30.5% ( n = 32/105; p < .0001 testing hypothesis H1: proportion >15%) following eltrombopag tapering and discontinuation, and median SRoT duration was ~8 months until Month 12. Median platelet count increased within 1 month of treatment and remained elevated until Month 12. Quality of life improved within 3 months and was maintained. Headache (21%) was the most common adverse event. None of the 4 deaths reported were considered treatment‐related. In summary, ~one‐third of patients achieved SRoT until Month 12 following eltrombopag tapering and discontinuation. An ad‐hoc early‐use analysis, stratified by ITP duration at baseline, assessed initial hematologic responses and safety. Results suggest that eltrombopag has similar efficacy in newly diagnosed and later stages of ITP. In follow‐up until Month 24, a median SRoT duration of ~22 months was observed ( n = 20). The safety profile was comparable across analyses and ITP duration groups and aligned with its well‐established safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaAdultHumansProspective StudiesQuality of LifeTreatment OutcomeBenzoatesHydrazinesSteroidsAdrenal Cortex HormonesPyrazoles

Substanzen

BenzoatesHydrazinesSteroidsAdrenal Cortex HormoneseltrombopagPyrazoles

Autor:innen und Institutionen

  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, UK.
  • Department of Haemato-Oncology, Østfold Hospital Trust, Kalnes, Grålum, Norway.
  • Department of Haematology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
  • Department of Hematology, Adnan Menderes University, Aydın, Turkey.

ORCID-Profile: Nichola Cooper, İrfan Yavaşoğlu

Förderung

  • NHLBI NIH HHS
  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Cooper, N., Ghanima, W., Vianelli, N., Valcárcel, D., Yavaşoğlu, İ., Melikyan, A., Ruiz, E. Y., Haenig, J., Somenzi, O., Lee, J., Clark, J., Zhang, Y., & Zaja, F. (2024). Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial. American Journal of Hematology, 99(1), 57-67. https://doi.org/10.1002/ajh.27131

Vancouver

Cooper N, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu İ, Melikyan A, et al. Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial. American Journal of Hematology. 2024;99(1):57-67. doi:10.1002/ajh.27131

BibTeX
@article{Cooper2024,
  author = {Cooper, Nichola and Ghanima, Waleed and Vianelli, Nicola and Valcárcel, David and Yavaşoğlu, İrfan and Melikyan, Anait and Ruiz, Eduardo Yañez and Haenig, Jens and Somenzi, Olivier and Lee, James and Clark, Joan and Zhang, Yifan and Zaja, Francesco},
  title = {Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {1},
  pages = {57--67},
  doi = {10.1002/ajh.27131}
}
Kostenlos starten →